Physician continuing education to reduce opioid misuse, abuse, and overdose: Many opportunities, few requirements

Drug and Alcohol Dependence

Volumn 163, Issue , 2016, Pages 100-107

  Davis, Corey S ^a   Carr, Derek ^a  

^a Network for Public Health Law   (United States)

Author keywords

Opioid; Overdose; Prescription drugs; Provider training

Indexed keywords

OPIATE; NARCOTIC ANALGESIC AGENT;

ANALGESIA; ARTICLE; CONTINUING EDUCATION; CONTROLLED STUDY; DRUG ABUSE; DRUG MISUSE; DRUG OVERDOSE; HUMAN; LAW; LICENCE; MEDICAL EDUCATION; PALLIATIVE THERAPY; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; SUBSTANCE ABUSE; UNITED STATES; DRUG LEGISLATION; INAPPROPRIATE PRESCRIBING; LICENSING; OPIOID-RELATED DISORDERS; PHYSICIAN; PRESCRIPTION DRUG MISUSE;

ANALGESICS, OPIOID; DRUG OVERDOSE; EDUCATION, MEDICAL, CONTINUING; HUMANS; INAPPROPRIATE PRESCRIBING; LEGISLATION, DRUG; LICENSURE; OPIOID-RELATED DISORDERS; PAIN MANAGEMENT; PHYSICIANS; PRESCRIPTION DRUG MISUSE; UNITED STATES;

EID: 84964573604     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2016.04.002     Document Type: Article

References (78)

1. Alford D.P., Zisblatt L., Ng P., Hayes S.M., Peloquin S., Hardesty I., White J.L. SCOPE of Pain: an evaluation of an opioid risk evaluation and mitigation strategy continuing education program. Pain Med. Epub a. 2015.
2. American Medical Association Continuing Medical Education for Licensure Reregistration 2014, AMA, Washington, DC.
3. American Medical Association National Survey Finds Physicians Support Pdmps, Encounter Barriers To Providing Non-Opioid Therapy To Treat Patients' Pain 2016, AMA, Washington, DC.
4. Association of American Medical Colleges Medicaid Direct And Indirect Graduate Medical Education Payements: A 50-State Survey 2010, AAMC, Washington, DC.
5. Attorney General Eric T. Schneiderman, 2016. A.G. Schneiderman Announces Settlement With Endo Health Solutions Inc. & Endo Pharmaceuticals Inc. Over Marketing Of Prescription Opioid Drugs. Albany, NY.
6. Baldwin G. Overview of the Public Health Burden of Prescription Drug and Heroin Overdoses. Food and Drug Administration: Exploring Naloxone Uptake and Use Public Meeting 2015, Silver Spring, MD.
7. Beauchamp G.A., Winstanley E.L., Ryan S.A., Lyons M.S. Moving beyond misuse and diversion: the urgent need to consider the role of iatrogenic addiction in the current opioid epidemic. Am. J. Public Health 2014, 104:2023-2029.
8. Bohnert A.S., Valenstein M., Bair M.J., Ganoczy D., McCarthy J.F., Ilgen M.A., Blow F.C. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011, 305:1315-1321.
9. Centers for Disease Control and Prevention Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR 2011, 60:1487-1492.
10. Centers for Disease Control and Prevention Vital signs: overdoses of prescription opioid pain relievers and other drugs among women-United States, 1999-2010. MMWR 2013, 62:537-542.
11. Centers for Disease Control and Prevention Draft CDC Guideline for Prescribing Opioids for Chronic Pain-United States, 2016 2015, CDC, Atlanta.
12. Centers for Disease Control and Prevention Number And Age-Adjusted Rates Of Drug-Poisoning Deaths Involving Opioid Analgesics And Heroin: United States, 2000-2014 2015, CDC, Atlanta.
13. Cervero R.M., Gaines J.K. The impact of CME on physician performance and patient health outcomes: an updated synthesis of systematic reviews. J. Contin. Educ. Health Prof. 2015, 35:131-138.
14. Chaparro L.E., Furlan A.D., Deshpande A., Mailis-Gagnon A., Atlas S., Turk D.C. Opioids compared with placebo or other treatments for chronic low back pain: an update of the Cochrane Review. Spine 2014, 39:556-563.
15. Cheatle M.D. Prescription opioid misuse, abuse, morbidity, and mortality: balancing effective pain management and safety. Pain Med. 2015, 16(Suppl. 1):S3-8.
16. Chou R., Turner J.A., Devine E.B., Hansen R.N., Sullivan S.D., Blazina I., Dana T., Bougatsos C., Deyo R.A. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann. Intern. Med 2015, 162:276-286.
17. Cicero T.J., Ellis M.S., Surratt H.L., Kurtz S.P. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry 2014, 71:821-826.
18. Cicero T.J., Ellis M.S., Harney J. shifting patterns of prescription opioid and heroin abuse in the United States. N. Engl J. Med. 2015, 373:1789-1790.
19. da Costa B.R., Nuesch E., Kasteler R., Husni E., Welch V., Rutjes A.W., Juni P. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst. Rev. 2014, 9. CD003115.
20. Dasgupta N., Creppage K., Austin A., Ringwalt C., Sanford C., Proescholdbell S.K. Observed transition from opioid analgesic deaths toward heroin. Drug Alcohol Depend. 2014, 145:238-241.
21. Daubresse M., Chang H.Y., Yu Y., Viswanathan S., Shah N.D., Stafford R.S., Kruszewski S.P., Alexander G.C. Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000-2010. Med. Care 2013, 51:870-878.
22. Davis C.S., Carr D. Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug Alcohol Depend. 2015, 157:112-120.
23. Davis C.S., Curtis J., Dunbar-Hester A. Leveraging the Affordable Care Act's nonprofit hospital requirements to expand access and improve health in low-income communities. Clearinghouse Rev. 2012, 45:403-410.
24. Davis C.S., Webb D., Burris S. Changing law from barrier to facilitator of opioid overdose prevention. J. Law Med. Ethics 2013, 41(Suppl. 1):33-36.
25. Davis C.S., Ruiz S., Glynn P., Picariello G., Walley A.Y. Expanded access to naloxone among firefighters police officers, and emergency medical technicians in Massachusetts. Am. J. Public Health 2014, 104:e7-9.
26. Department of Health and Human Services, Office of the Inspector General Department of Health FDA Lacks Comprehensive Data To Determine Whether Risk Evaluation And Mitigation Strategies Improve Drug Safety 2013, DHHS, Washington, DC.
27. Doorenbos A.Z., Gordon D.B., Tauben D., Palisoc J., Drangsholt M., Lindhorst T., Danielson J., Spector J., Ballweg R., Vorvick L., Loeser J.D. A blueprint of pain curriculum across prelicensure health sciences programs: one NIH Pain Consortium Center of Excellence in Pain Education (CoEPE) experience. J. Pain 2013, 14:1533-1538.
28. Dowell D., Haegerich T.M., Chou R. CDC guideline for prescribing opioids for chronic pain-United States. MMWR Rec. Rep. 2016, 65:1-49.
29. Elhwairis H., Reznich C.B. An educational strategy for treating chronic, noncancer pain with opioids: a pilot test. J. Pain 2010, 11:1368-1375.
30. Executive Office of the President Epidemic: Responding to America's Prescription Drug Abuse Crisis 2011, Office of National Drug Control Policy, Washington, D.C.
31. Federation of State Medical Boards Continuing Medical Education: Board by Board Overview 2015, Federation of State Medical Boards, Washington, DC.
32. Girion L. Judge halts counties' lawsuit against 5 narcotic drug manufacturers 2015, Los Angeles Times.
33. Green T.C., Dauria E.F., Bratberg J., Davis C.S., Walley A.Y. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduct. J. 2015, 12:25.
34. Health Affairs, 2012. Health Policy Brief: Graduate Medical Education.
35. Hedegaard H., Chen L.H., Warner M. Drug-poisoning deaths involving heroin: United States, 2000-2013. NCHS Data Brief 2015, 1-8.
36. Hooten W.M., Bruce B.K. Beliefs and attitudes about prescribing opioids among healthcare providers seeking continuing medical education. J. Opioid Manag. 2011, 7:417-424.
37. Hwang C.S., Turner L.W., Kruszewski S.P., Kolodny A., Alexander G.C. Primary care physicians' knowledge and attitudes regarding prescription opioid abuse and diversion. Clin. J. Pain 2015, 32:279-284.
38. Institute of Medicine (U.S.) and Committee on Advancing Pain Research Care and Education Relieving Pain In America: A Blueprint For Transforming Prevention, Care, Education, And Research 2011, National Academies Press, Washington, D.C.
39. Insys Therapeutics, I., 2015. Form 10-Q. Phoenix, AZ.
40. Johns Hopkins Bloomberg School of Public Health The Prescription Opioid Epidemic: An Evidence-Based Approach 2015, Johns Hopkins Bloomberg School of Public Health, Baltimore.
41. Jones C., Logan J., Gladden R., Bohm M. Vital signs: demographic and substance use trends among heroin users-United States, 2002-2013. MMWR 2015, 64:719-725.
42. Kaplovitch E., Gomes T., Camacho X., Dhalla I.A., Mamdani M.M., Juurlink D.N. Sex differences in dose escalation and overdose death during chronic opioid therapy: a population-based cohort study. PLoS One 2015, 10:e0134550.
43. Katz J.A., Swerdloff M.A., Brass S.D., Argoff C.E., Markman J., Backonja M., Katz N. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology 2015, 84:1503-1504.
44. Katzman J.G., Comerci G.D., Landen M., Loring L., Jenkusky S.M., Arora S., Kalishman S., Marr L., Camarata C., Duhigg D., Dillow J., Koshkin E., Taylor D.E., Geppert C.M. Rules and values: a coordinated regulatory and educational approach to the public health crises of chronic pain and addiction. Am. J. Public Health 2014, 104:1356-1362.
45. Keller C.E., Ashrafioun L., Neumann A.M., Van Klein J., Fox C.H., Blondell R.D. Practices, perceptions, and concerns of primary care physicians about opioid dependence associated with the treatment of chronic pain. Subst. Abuse 2012, 33:103-113.
46. Kentucky Office of the Attorney General AG Conway Announces Two Pharmaceutical Settlements Totaling $39.5 Million 2015, Kentucky Office of the Attorney General, Frankfort, KY.
47. Kolodny A., Courtwright D.T., Hwang C.S., Kreiner P., Eadie J.L., Clark T.W., Alexander G.C. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Ann. Rev. Public Health 2015, 36:559-574.
48. Kuehn B.M. FDA opioid safety plan promotes patient, physician education to prevent abuse. JAMA 2010, 304:845.
49. Kuehn B.M. Successes, challenges emerge from efforts to shift away from industry-funded CME. JAMA 2010, 304:729-731.
50. Kuehn B.M. SAMHSA: Pain medication abuse a common path to heroin: experts say this pattern likely driving heroin resurgence. JAMA 2013, 310:1433-1434.
51. Leong L., Ninnis J., Slatkin N., Rhiner M., Schroeder L., Pritt B., Kagan J., Ball T., Morgan R. Evaluating the impact of pain management (PM) education on physician practice patterns-a continuing medical education (CME) outcomes study. J. Cancer Educ. 2010, 25:224-228.
52. Lum P.J., Little S., Botsko M., Hersh D., Thawley R.E., Egan J.E., Mitty J., Boverman J., Fiellin D.A., Collaborative B. Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings. J. Acquir. Immune Defic. Syndr. 2011, 56(Suppl. 1):S91-97.
53. Mazer-Amirshahi M., Mullins P.M., Rasooly I., van den Anker J., Pines J.M. Rising opioid prescribing in adult U.S. emergency department visits: 2001-2010. Acad. Emerg. Med 2014, 21:236-243.
54. Meier B. In guilty plea, OxyContin maker to pay $600 million 2007, New York Times.
55. Mezei L., Murinson B.B. Johns hopkins pain curriculum development team 2011 pain education in north American medical schools. J. Pain 2011, 12:1199-1208.
56. Miller N.S., Sheppard L.M., Colenda C.C., Magen J. Why physicians are unprepared to treat patients who have alcohol- and drug-related disorders. Acad. Med. 2001, 76:410-418.
57. Muchmore S. Educate doctors, treat addicts to curb opioid abuse, lawmakers told. Mod. Healthc. 2016, http://www.modernhealthcare.com/article/20160127/NEWS/160129881.
58. The National Center on Substance Abuse at Columbia University Missed Opportunity: National Survey Of Primary Care Physicians And Patients On Substance Abuse 2000, National Center on Substance Abuse at Columbia University, New York.
59. New York State Office of the Attorney General A.G. Schneiderman Announces Settlement With Purdue Pharma That Ensures Responsible And Transparent Marketing Of Prescription Opioid Drugs By The Manufacturer 2015, New York State Office of the Attorney General, Albany.
60. O'Connor P.G., Nyquist J.G., McLellan A.T. Integrating addiction medicine into graduate medical education in primary care: the time has come. Ann. Intern. Med. 2011, 154:56-59.
61. Obama, B., 2015. Presidential Memorandum-Addressing Prescription Drug Abuse and Heroin Use. Washington, D.C. http://https://www.whitehouse.gov/the-press-office/2015/10/21/presidential-memorandum-addressing-prescription-drug-abuse-and-heroin.
62. Obama, B., 2016. Fact Sheet: Obama Administration Announces Additional Actions to Address the Prescription Opioid Abuse and Heroin Epidemic. Washington, D.C. http://https://www.whitehouse.gov/the-press-office/2016/03/29/fact-sheet-obama-administration-announces-additional-actions-address.
63. Oregon Department of Justice AG Rosenblum Settles with Pharmaceutical Company Insys over Unlawful Promotion of the Powerful Opioid Subsys 2015, Oregon Department of Justice, Salem.
64. Pokorny A., Putnam P., Fryer J. Drug abuse and alcoholism teaching in U.S. medical and osteopathic schools. J. Med. Educ. 1978, 53:816-824.
65. Polydorou S., Gunderson E.W., Levin F.R. Training physicians to treat substance use disorders. Curr. Psychiatry Rep. 2008, 10:399-404.
66. Rich E.C., Liebow M., Srinivasan M., Parish D., Wolliscroft J.O., Fein O., Blaser R. Medicare financing of graduate medical education. J. Gen. Intern. Med. 2002, 17:283-292.
67. Rudd R.A., Aleshire N., Zibbell J.E., Gladden M. Increases in drug and opioid overdose deaths-United States, 2000-2014. MMWR 2015, 64:1-5.
68. Swiggart W.H., Ghulyan M.V., Dewey C.M. Using standardized patients in continuing medical education courses on proper prescribing of controlled substances. Subst. Abuse 2012, 33:182-185.
69. Tauben D.J., Loeser J.D. Pain education at the university of washington school of medicine. J. Pain 2013, 14:431-437.
70. United States Food, Drug Administration Questions and Answers: FDA Approves a Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting (ER/LA) Opioid Analgesics 2012, FDA, Washington, DC.
71. Upshur C.C., Luckmann R.S., Savageau J.A. Primary care provider concerns about management of chronic pain in community clinic populations. J. Gen. Intern. Med. 2006, 21:652-655.
72. Ury W.A., Rahn M., Tolentino V., Pignotti M.G., Yoon J., McKegney P., Sulmasy D.P. Can a pain management and palliative care curriculum improve the opioid prescribing practices of medical residents?. J. Gen. Intern. Med. 2002, 17:625-631.
73. Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am. J. Public Health 2009, 99:221-227.
74. Vowles K.E., McEntee M.L., Julnes P.S., Frohe T., Ney J.P., van der Goes D.N. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 2015, 156:569-576.
75. Wagenaar A.C., Burris S. Public health law research: theory and methods 2013, Jossey-Bass, San Francisco, CA.
76. Wakeman S.E., Baggett M.V., Pham-Kanter G., Campbell E.G. Internal medicine residents' training in substance use disorders: a survey of the quality of instruction and residents' self-perceived preparedness to diagnose and treat addiction. Subst. Abuse 2013, 34:363-370.
77. Weeks C. College of Family Physicians rejects call for mandatory course on safe opioid prescribing 2016, The Globe and Mail.
78. Yanni L.M., McKinney-Ketchum J.L., Harrington S.B., Huynh C., Amin Bs S., Matsuyama R., Coyne P., Johnson B.A., Fagan M., Garufi-Clark L. Preparation, confidence, and attitudes about chronic noncancer pain in graduate medical education. J. Grad. Med. Educ. 2010, 2:260-268.